No Data
Novo Nordisk revolutionary weight loss therapy CagriSema is coming! Can it reshape the market landscape?
Novo Nordisk is eager to prove the superiority of its new product Cagrilin peptide in a mixture with semaglutide before December, in order to maintain its leading position in the field of obesity treatment.
Viking Therapeutics (VKTX.US) weight loss drug emerging unexpectedly, challenging the traditional leaders in the field.
The data released earlier on Monday by viking therapeutics on the weight-loss drug VK2735 indicates that novo-nordisk a/s and eli lilly and co, currently dominating the obesity drug market, may face fierce competition in the future.
Futu Morning Post | Countdown to the election! The panic index VIX is burning high and uncertainty is haunting the market nerves; Up nearly 13% after hours! Palantir raises full-year revenue guidance
Jpmorgan warns: If Trump wins on Wednesday, the Fed may pause the easing cycle as early as December; Will the US stock market hit new highs after the election? Jpmorgan: FOMO psychology boosts, S&P may hit 6100 points by the end of the year; US polls: Harris and Trump are neck and neck in key 'swing states'.
US stocks closed: Trump, Harris concept stocks rose together, Chinese concept stocks remained stable and rose.
1. The market is filled with a wait-and-see attitude, with all three major indexes collectively falling. 2. Trump's media technology group rebounded after hitting bottom. 3. Photovoltaic and clean energy concept stocks strengthened collectively. 4. Reports claim that Nvidia will distribute Super Micro Computer orders to other suppliers.
How Does Viking's Weight Loss Med Compare to Ones From Novo, Eli Lilly?
Viking Stock Drops 13% After Jumping 9% on Obesity Drug Data